

Patricia M Day

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2883623/publications.pdf>

Version: 2024-02-01

24
papers

1,996
citations

394421

19
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1662
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracellular Localization of Proteasomal Degradation of a Viral Antigen. <i>Journal of Cell Biology</i> , 1999, 146, 113-124.	5.2	205
2	Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14252-14257.	7.1	204
3	Papillomaviruses infect cells via a clathrin-dependent pathway. <i>Virology</i> , 2003, 307, 1-11.	2.4	190
4	Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies. <i>Journal of Virology</i> , 2008, 82, 4638-4646.	3.4	149
5	In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection. <i>Cell Host and Microbe</i> , 2010, 8, 260-270.	11.0	148
6	Large Scale RNAi Reveals the Requirement of Nuclear Envelope Breakdown for Nuclear Import of Human Papillomaviruses. <i>PLoS Pathogens</i> , 2014, 10, e1004162.	4.7	135
7	Heparan Sulfate-Independent Cell Binding and Infection with Furin-Precleaved Papillomavirus Capsids. <i>Journal of Virology</i> , 2008, 82, 12565-12568.	3.4	133
8	Identification of a Role for the <i>trans</i> -Golgi Network in Human Papillomavirus 16 Pseudovirus Infection. <i>Journal of Virology</i> , 2013, 87, 3862-3870.	3.4	125
9	Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. <i>Journal of Clinical Investigation</i> , 2012, 122, 4606-4620.	8.2	120
10	Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of Inhibition. <i>Journal of Virology</i> , 2007, 81, 8784-8792.	3.4	116
11	A Human Papillomavirus (HPV) <i>In Vitro</i> Neutralization Assay That Recapitulates the <i>In Vitro</i> Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting Antibodies. <i>Vaccine Journal</i> , 2012, 19, 1075-1082.	3.1	78
12	Concepts of papillomavirus entry into host cells. <i>Current Opinion in Virology</i> , 2014, 4, 24-31.	5.4	69
13	The role of furin in papillomavirus infection. <i>Future Microbiology</i> , 2009, 4, 1255-1262.	2.0	60
14	Strain-Specific Properties and T Cells Regulate the Susceptibility to Papilloma Induction by <i>Mus musculus</i> Papillomavirus 1. <i>PLoS Pathogens</i> , 2014, 10, e1004314.	4.7	59
15	Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. <i>Vaccine</i> , 2014, 32, 3540-3547.	3.8	39
16	A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells. <i>Journal of Immunology</i> , 2019, 202, 1250-1264.	0.8	34
17	Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	31
18	Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions. <i>PLoS ONE</i> , 2014, 9, e101576.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism. <i>Journal of Virology</i> , 2017, 91, .	3.4	22
20	Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 74-89.	4.5	14
21	A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging. <i>Journal of Virology</i> , 2016, 90, 1096-1107.	3.4	14
22	The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane. <i>Virology</i> , 2015, 481, 79-94.	2.4	11
23	Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 5, 165-179.	4.1	11
24	Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions. <i>Journal of Virology</i> , 2022, 96, e0185721.	3.4	7